What Happened?
Cambridge, -based Beigene Resigned Mark Dizon as Assistant General Counsel and Chief Compliance Officer
Date of management change: August 24, 2022
Cambridge, -based Beigene Resigned Mark Dizon as Assistant General Counsel and Chief Compliance Officer
Beigene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.
Mark Dizon is General Counsel at Frontier Medicines. Previously, Mark held various senior legal leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Wagner Stuart, Krieger Sanford, Walters Elizabeth, James Moji, Koonce Kara, Harter Ava, Villarreal Jaime, Borgquist Karl, Raby Deitzah, Harbaugh Jenna, Barnes Stephanie
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.